The suit has been filed in the U.S. District Court for the District of Columbia against Cephalon. According to the Commission, Cephalon, faced with threat to its Provigil monopoly, paid more than $200 million to generic drug companies to abandon their patent challenges and forgo entry into the market until April 2012. As Cephalon's CEO allegedly put it shortly after entering these settlements: "We were able to get six more years of patent protection. That's $4 billion in sales no one expected".
The FTC is clearly taking the issue very seriously, see also here.
Subscribe to:
Post Comments (Atom)
-
https://cartography-of-generative-ai.net/ CEPR, here. I particularly appreciated Jonathan Kanter's opening remark, which subtly quest...
-
R. Jahangir, here.
-
ChinaTalk, here.
-
Here . Timing was, well, bad (into Friday evening my time, European after all and cherish my off-work time) - followed 1/3 of it and was v...
-
M. Singh, here.
-
EC, here.
No comments:
Post a Comment